KOSPIApparel & Living012690

Monalisa

₩1,262▼ 1.33%2026-11-18 close
Market Cap
₩46.2B
Turnover
₩100M
Volume
80K
Shares out.
36.6M
PER
20.0×
PBR
0.5×
EPS
₩64
Dividend Yield
3.91%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit Recovery Amid Flat Sales at a Tissue Maker

Monalisa has posted positive quarterly operating profit through the third quarter of 2026, but sales have stayed in the KRW 124 billion to KRW 126.3 billion range since the 2023 peak, so a top-line recovery is not yet visible.

  1. 1

    Sales peaked at KRW 129.8 billion in 2023 and declined for two consecutive years from 2024 to 2025, reaching KRW 124 billion in 2025.

  2. 2

    Operating profit was highest in 2023 at KRW 6.49 billion and lowest in 2025 at KRW 317 million, and the 2025 operating margin was 0.3%.

  3. 3

    Quarterly operating profit was KRW 326 million in the first quarter of 2026, KRW 1.12 billion in the second and KRW 297 million in the third, with the third quarter down 73.4% from the prior quarter.

  4. 4

    Total equity at the end of 2025 was KRW 87.4 billion against total liabilities of KRW 13.1 billion, a balance sheet cited as a buffer against earnings swings.

  5. 5

    Whether and how much to pay in dividends for 2026 has not been decided, and the expansion of the premium Paseo line runs through 2028.

02

Business structure

Monalisa is a consumer hygiene company centered on tissue and kitchen towels, classified in the KOSPI paper and wood sector. According to a company profile aggregator, product sales account for about 69% of revenue, merchandise about 16.5%, semi-finished goods about 13% and other items about 1%.

Domestic sales dominate, with domestic sales of roll products exceeding 99% as of December 2025. In July 2025 the company launched a pocket bidet wipe and an all-in-one disposable scrubber, and in November 2025 a pull-out bamboo kitchen towel.

In June 2025 it recorded a first place in the tissue category of a national consumer satisfaction award for household goods. The tissue market is gradually shifting from three-ply toward four-ply products, and the premium Paseo line is the company's response.

Roughly KRW 8 billion was invested in a dedicated Paseo production line, and the company plans to widen sales through B2B channels such as hotels, resorts and golf clubs. Private-label products from distributors are spreading, making cost control and distribution access the main challenges in tissue.

Because manufacturing costs are heavy, swings in pulp prices and logistics costs pass quickly into profit. In November 2025 the company received an integrated A grade from the Korea ESG Standards Institute's evaluation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩31B₩11,633,1760.0%
2025Q4₩31.6B₩300M0.8%
2026Q1₩32.3B₩300M1.0%
2026Q2₩34.5B₩1.1B3.2%
2026Q3₩32.5B₩300M0.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩120.9B₩2.9B₩2.3B2.4%3.0%26.0%
2023₩129.8B₩6.5B₩9.1B5.0%11.2%19.4%
2024₩126.3B₩1B₩1.2B0.8%1.5%20.4%
2025₩124B₩300M₩1.5B0.3%1.7%15.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported basis, sales rose from KRW 120.9 billion in 2022 to KRW 129.8 billion in 2023, which was the largest year in the period, then fell to KRW 126.3 billion in 2024 and KRW 124 billion in 2025, a decline in 2024 and 2025 that was two consecutive years.

Operating profit went from KRW 2.9 billion in 2022 to KRW 6.49 billion in 2023, up 124.0%, then to KRW 983 million in 2024 and KRW 317 million in 2025, making 2025 the smallest year in the period.

The operating margin moved from 2.4% in 2022 to 5.0% in 2023, 0.8% in 2024 and 0.3% in 2025, so margin compression explains more of the profit decline than the modest sales decline.

Profit attributable to controlling shareholders was KRW 2.34 billion in 2022, KRW 9.14 billion in 2023, the largest year, KRW 1.24 billion in 2024, the smallest, and KRW 1.5 billion in 2025, a partial recovery.

Net income including non-controlling interests was recorded at KRW 2.34 billion, KRW 9.14 billion, KRW 1.24 billion and KRW 1.5 billion for the same years.

The debt ratio fell from 26.0% in 2022 to 15.0% in 2025, and at the end of 2025 total equity was KRW 87.4 billion, all attributable to controlling shareholders, against total liabilities of KRW 13.1 billion.

Operating cash flow was KRW 6.57 billion in 2022, KRW 7.09 billion in 2023, KRW 4.26 billion in 2024 and KRW 2.59 billion in 2025, declining since 2023.

Quarterly sales were KRW 31 billion in the third quarter of 2025, KRW 31.6 billion in the fourth quarter (up 1.9% from the prior quarter), KRW 32.3 billion in the first quarter of 2026 (up 2.3%), KRW 34.5 billion in the second quarter of 2026 (up 6.9%), and KRW 32.5 billion in the third quarter of 2026 (down 5.9% from the prior quarter, up 4.8% year on year).

Quarterly operating profit went from KRW 11.63 million in the third quarter of 2025 to KRW 252 million in the fourth quarter, KRW 326 million in the first quarter of 2026 and KRW 1.12 billion in the second quarter, then KRW 297 million in the third quarter.

Press coverage of the first quarter of 2026 attributed the swing to profit to a drop in the cost of sales ratio from 81.25% to 75.50%, while the selling and administrative expense ratio rose from 19.95% to 23.48%.

Profit attributable to controlling shareholders was KRW 118 million, KRW 1.08 billion, KRW 337 million, KRW 591 million and KRW 307 million across the five quarters from the third quarter of 2025 to the third quarter of 2026, and the last four quarters total KRW 2.32 billion.

05

Industry analysis

Demand for tissue products is sensitive to consumer sentiment and the domestic economy, and the company's 2025 business summary cites weak domestic demand, higher energy prices and currency pressure together as factors that lowered sales and profitability.

A company profile aggregator's 2025 year-end commentary pointed to currency volatility, weaker consumer sentiment, and rising pulp and logistics costs as drags on sales and profit. Pulp prices and currency pressure have been reported as rising again in 2026.

Analysts see a broader base for adult diapers, supported by an aging society and welfare support systems, with stable growth expected. Against peers, the company posted positive operating profit in the first quarter of 2026 while several competitors reported operating losses over the same period.

Its debt-free structure and retained earnings of roughly KRW 50 billion were cited as support for shareholder return capacity.

In terms of cycle position, sales have stalled in the KRW 120 billion to KRW 130 billion range since the 2023 peak, with quarterly sales peaking at KRW 34.5 billion in the second quarter of 2026 before falling to KRW 32.5 billion in the third quarter.

06

Outlook

The one investment plan the company has publicly outlined is expanding production capacity for its premium Paseo line, which is set to phase in from 2026 through 2028. The company has also prepared to add production days as demand grows.

It plans to widen sales through B2B channels such as hotels, resorts and golf clubs, and talks with some hotels about placing its products in guest rooms are under way. The strategy adds premium products such as Paseo to the existing core lineup in order to lift overall market share and sales.

The company has paid cash dividends in 2021 (KRW 2.7 billion), 2023 (KRW 5.5 billion) and 2024 (KRW 3.8 billion). Whether and how much to pay for 2026 has not been decided, and the company says the decision will weigh its investment plans and external conditions.

On financial capacity, cash and cash equivalents were KRW 12.6 billion and operating cash flow was positive for three consecutive years as of the end of 2025. Operating cash flow fell from KRW 7.09 billion in 2023 to KRW 2.59 billion in 2025, so whether that trend continues is the next point to track.

Whether the Paseo expansion lifts sales and profit as capacity comes online through 2028 remains the open question.

07

Valuation

PER
20.0×
PBR
0.5×
ROE
2.8%
EPS
₩64
BPS
₩2,378
Dividend per share
₩50

Market capitalization is currently below total equity at the end of 2025 of KRW 87.4 billion, so the price-to-book ratio sits under 1x. Among the factors pushing the market price below book value are the shrinking operating margin and stalled sales.

Profit is small, with the last four quarters' profit attributable to controlling shareholders totaling KRW 2.32 billion, so earnings-based multiples move sharply with small changes in profit.

Profit attributable to controlling shareholders peaked at KRW 9.14 billion in 2023 and was KRW 1.5 billion in 2025, a gap large enough that comparisons with past multiples are difficult.

The company has paid dividends in 2021, 2023 and 2024, but the 2026 payment is still undecided, so comparisons based on dividends can only be made after that decision. The debt ratio of 15.0% in 2025 indicates a light debt burden, while the 0.3% operating margin leaves a thin profit base.

Profit has moved in a recovery direction since 2024, and the string of positive quarterly operating results in 2026 reflects that shift.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly profit held and cost ratio improved

Operating profit turned positive at KRW 326 million in the first quarter of 2026 and rose to KRW 1.12 billion in the second quarter. Press coverage said the cost of sales ratio fell from 81.25% to 75.50%, and that cost savings offset higher expenses in the first quarter. The third quarter of 2026 still posted positive operating profit of KRW 297 million.

Debt-free structure and retained earnings base

The debt ratio fell to 15.0% in 2025 from 26.0% in 2022, and total liabilities were KRW 13.1 billion at the end of 2025. Press coverage said retained earnings rose steadily over five years to reach KRW 56.4 billion in 2025 in a company without borrowings. Cash and cash equivalents were KRW 12.6 billion. Operating cash flow stayed positive for three straight years.

Premium Paseo line and B2B channels

With dedicated Paseo equipment in place, production capacity is planned to expand in phases through 2028. The company also plans to extend premium products into B2B channels such as hotels, resorts and golf clubs. The shift in the market from three-ply to four-ply products could form a demand base for the higher-end line.

09

Bear factors

Flat sales and shrinking margins

Sales peaked at KRW 129.8 billion in 2023 and fell in both 2024 and 2025. The 2025 operating margin was 0.3%, with operating profit of KRW 317 million, the smallest in the period.

Third-quarter 2026 sales fell 5.9% from the prior quarter, and profit attributable to controlling shareholders dropped 48.1% to KRW 307 million.

Renewed pressure from pulp, currency and logistics

The 2025 year-end commentary named currency swings, pulp prices and higher logistics costs as drags on sales and profit. Pulp prices and currency pressure have been reported as rising again in 2026. Logistics costs within selling and administrative expenses rose from KRW 3.1 billion to KRW 3.6 billion. The downside is that the cost ratio gains could be eroded by these pressures again.

Private-label spread and weaker consumer sentiment

In tissue, the spread of distributor private-label products has made cost control and distribution access the main challenges. Weaker consumer sentiment was also recorded as a factor lowering sales and profit. With a heavily domestic sales base, the company is directly exposed to domestic slowdowns. Third-quarter 2026 operating profit of KRW 297 million was down 73.4% from the prior quarter.

10

Risk factors

Raw material, currency and logistics risk

Press reports say pulp prices and currency pressure have risen again in 2026. Higher raw material and logistics costs hit both cost of sales and selling expenses at once. The 2025 year-end commentary also named pulp and logistics costs as profit drags. How far the cost ratio gains can absorb these costs is the key question.

Distribution structure and domestic concentration risk

The spread of distributor private-label products makes cost control and distribution access harder. Domestic sales of roll products exceed 99%, so concentration in the home market is very high. With limited overseas sales, the buffer against domestic demand swings is limited.

Earnings volatility and dividend uncertainty

Profit attributable to controlling shareholders fell from KRW 591 million in the second quarter of 2026 to KRW 307 million in the third. Operating cash flow fell from KRW 6.57 billion in 2022 to KRW 2.59 billion in 2025. Whether and how much to pay for 2026 has not been decided. Past dividend decisions have weighed operating results heavily.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report, which will confirm full-year 2026 sales and operating margin, including the fourth quarter, and show whether and how much dividend was decided for 2026.

  2. Mid-May 2027

    Q1 2027 quarterly report. It serves as a check on cost continuity against the first-quarter 2026 base, when the cost of sales ratio was 75.50% and the selling and administrative expense ratio was 23.48%.

  3. During 2027

    Progress on phased production expansion at the dedicated Paseo line and B2B channel contracts with hotels and resorts, through 2028, and whether these show up in quarterly sales.

  4. Mid-August 2027

    Q2 2027 quarterly report. It shows whether operating profit holds near the KRW 1.12 billion of the second quarter of 2026 or the decline seen in the third quarter continues.

12

Overall view

Monalisa's sales peaked at KRW 129.8 billion in 2023 and declined in 2024 and 2025, while the operating margin fell from 5.0% in 2023 to 0.3% in 2025. Quarterly operating profit stayed positive through 2026, at KRW 326 million in the first quarter, KRW 1.12 billion in the second and KRW 297 million in the third.

Press coverage attributed the first-quarter swing to profit to a cost ratio decline that outweighed higher selling expenses. Profit attributable to controlling shareholders totaled KRW 2.32 billion over the last four quarters and fell in the third quarter of 2026 from the prior quarter.

Strengths on the financial side include a 15.0% debt ratio, a debt-free structure and retained earnings. Weaknesses are stalled sales, pulp, currency and logistics pressure, and structural change from private-label spread.

Expansion of the Paseo line and B2B channels runs through 2028, and how much this shows up in sales and profit is the next point to track.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. comp.wisereport.co.kr
  4. comp.fnguide.com
  5. accidentalorder.com
  6. ibtomato.com
  7. comp.fnguide.com
  8. sedaily.com
  9. edaily.co.kr
  10. newswire.co.kr
  11. tradingkey.com
  12. globenewswire.com
  13. tradingkey.com
  14. etoday.co.kr
  15. globenewswire.com
  16. m.thinkpool.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis